IDH2 and glioma: While targeted therapies have become standard-of-care in other molecularly-defined cancers (such as EGFR-mutant lung cancers, HER2-positive cancers, and even other IDH-mutant cancers), drugs that target supposed driver mutations in glioma had not demonstrated clinically significant benefits until recently.